ArticleMolecular medicine (Cambridge, Mass.)2026
Dissecting the small RNA code of inflammatory bowel disease.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEmerging evidence demonstrates that noncanonical small noncoding RNAs (sncRNAs), including tRNA-derived small RNAs (tsRNAs), rRNA-derived small RNAs (rsRNAs), and Y RNA-derived small RNAs (ysRNAs), are highly abundant in various tissues and cell types and play critical roles in numerous biological processes. These noncanonical sncRNAs are also present in bodily fluids with great potential as disease biomarkers.
methodsWe leveraged an existing sncRNA dataset to characterize the profiles of tsRNAs, rsRNAs, and ysRNAs in the peripheral blood of patients with inflammatory bowel disease (IBD)—comprising both ulcerative colitis (UC) and Crohn’s disease (CD)—alongside healthy controls (HCs) and symptomatic controls (SCs) within a Swedish cohort (n = 205).
resultsOur analysis revealed an overall similar dysregulation pattern of noncanonical sncRNAs among the UC, CD, and SC samples compared to HCs. Our co-expression analysis between sncRNAs and genes suggests elevated oxidative stress as a potential universal regulator of tsRNA/rsRNA/ysRNA biogenesis in IBD. Further, we developed a molecular signature composed of 21 tsRNA/rsRNA/ysRNA families, which clearly distinguished IBD patients from HCs in the Swedish cohort. However, this signature showed a diminished signal in a German cohort (n = 242), in which the IBD patients were treatment-exposed. As a comparison, a 25-miRNA based signature was also developed, which also showed a fairly good classification power between HCs and patients in the Swedish cohort, but was less robust reflected by a stronger baseline divergence between the Swedish and German cohorts.
conclusionsOur findings suggest the potential of tsRNA/rsRNA/ysRNA profiles as biomarkers for IBD and provide clues for further functional and mechanistic investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.